Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00043
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
68Ga-PSMA-11
|
|||||
| Synonyms |
68Ga-Psma-11; Gallium Ga-68 gozetotide; Prostamedix; Gallium (68Ga) gozetotide; 68ga-psma-hbed-cc; (68Ga)Hbed-psma; UNII-ZJ0EKR6M10; (68ga)psma-hbed-cc; psma-hbed-cc ga-68; ZJ0EKR6M10; Gallium Ga 68 gozetotide; Gallium gozetotide Ga-68; Ga-Psma-hbed-CC Ga-68; Ga-68-Labeled PSMA-11; Gallium-68 PSMA; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 PSMA-11; PSMA-11 Ga 68; PSMA-11 Ga-68; DKFZ-PSMA-11 GA-68; 68Ga-Labelled Glu-urea-Lys(ahx)-hbed-CC; Glu-urea-Lys(ahx)-hbed-CC Ga-68; LOCAMETZ; Glu-NH-CO-NH-Lys-(ahx)-(68Ga(hbed-CC)); (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC; 1906894-20-9; Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC; Gallium Ga 68 gozetotide [USAN]; GaPSMA; ILLUCCIX; Ga PSMA; Gallium 68 Psma-11; Gallium ga-68 psma-11; 68Ga-HBED-CC-PSMA; (68Ga)GaPSMA-11; Ga-68 labeled PSMA-11; Gallium Ga 68 PSMA-11; Ga-68 labeled DKFZ-PSMA-11; Gallium Ga 68-labeled PSMA-11; Gallium (68Ga) gozetotide [INN]; WHO 11504; (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC; (68Ga) Prostate-specific Membrane Antigen 11; 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; GALLATE(5-)-68GA, (N-((((1S)-1-CARBOXY-5-((6-((3-(3-(((2-(((5-(2-CARBOXYETHYL)-2-(HYDROXY-kappaO)PHENYL)METHYL)((CARBOXY-kappaO)METHYL)AMINO-kappaN)ETHYL)((CARBOXY-kappaO)METHYL)AMINO-kappaN)METHYL)-4-(HYDROXY-kappaO)PHENYL)-1-OXOPROPYL)AMINO)-1-OXOHEXYL)AMINO)PENTYL)AMINO)CARBONYL)-L-GLUTAMATO(8-))-, HYDROGEN (1:5)
Click to Show/Hide
|
|||||
| PDC Status |
Approved
|
|||||
| Structure |
|
|||||
| Peptide Name |
PSMA-617
|
Peptide Info | ||||
| Receptor Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Receptor Info | ||||
| Drug Name |
Gallium-68
|
Drug Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Aminocaproic acid
|
Linker Info | ||||
| Absorption |
Following intravenous injection, Ga-68 PSMA-11 uptake occurs in the adrenal and prostate glands, with high uptake in PSMA-expressing tissues. Uptake of the drug is very minimal in the cerebral cortex, heart, and lungs. Mean maximum standardized uptake value (SUVmax) at later acquisition times is about 15.3.
|
|||||
| Distribution |
Ga-68 PSMA-11 accumulates in the liver (15%), kidneys (7%), spleen (2%), and salivary glands (0.5%). Ga-68 PSMA-11 accumulation increases at later acquisition times.
|
|||||
| Metabolism |
Ga-68 PSMA-11 decays to stable zinc-68.
|
|||||
| Excretion |
About 14% of the total injected dose is excreted in the urine within two hours following intravenous administration.
|
|||||
| Drugbank ID | ||||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
| Formula |
C44H59GaN6O17
|
|||||
| #Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 1011.9 | ||||
| Lipid-water partition coefficient (xlogp) | Not Available | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 9 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 19 | |||||
| Rotatable Bond Count (rotbonds) | 33 | |||||